199 related articles for article (PubMed ID: 24779718)
1. microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway.
Mitamura T; Watari H; Wang L; Kanno H; Kitagawa M; Hassan MK; Kimura T; Tanino M; Nishihara H; Tanaka S; Sakuragi N
Mol Cancer; 2014 Apr; 13():97. PubMed ID: 24779718
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
[TBL] [Abstract][Full Text] [Related]
3. Hippo signaling pathway reveals a spatio-temporal correlation with the size of primordial follicle pool in mice.
Xiang C; Li J; Hu L; Huang J; Luo T; Zhong Z; Zheng Y; Zheng L
Cell Physiol Biochem; 2015; 35(3):957-68. PubMed ID: 25659841
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2.
Song L; Huang Y; Zhang X; Han S; Hou M; Li H
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):32. PubMed ID: 32186675
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway.
Xia X; Li Y; Wang W; Tang F; Tan J; Sun L; Li Q; Sun L; Tang B; He S
Mol Cancer; 2015 Aug; 14():154. PubMed ID: 26265437
[TBL] [Abstract][Full Text] [Related]
6. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma.
Sohn BH; Shim JJ; Kim SB; Jang KY; Kim SM; Kim JH; Hwang JE; Jang HJ; Lee HS; Kim SC; Jeong W; Kim SS; Park ES; Heo J; Kim YJ; Kim DG; Leem SH; Kaseb A; Hassan MM; Cha M; Chu IS; Johnson RL; Park YY; Lee JS
Clin Cancer Res; 2016 Mar; 22(5):1256-64. PubMed ID: 26459179
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
9. The cell polarity protein Scrib functions as a tumor suppressor in liver cancer.
Kapil S; Sharma BK; Patil M; Elattar S; Yuan J; Hou SX; Kolhe R; Satyanarayana A
Oncotarget; 2017 Apr; 8(16):26515-26531. PubMed ID: 28460446
[TBL] [Abstract][Full Text] [Related]
10. Effects of the hippo signaling pathway in human gastric cancer.
Zhou GX; Li XY; Zhang Q; Zhao K; Zhang CP; Xue CH; Yang K; Tian ZB
Asian Pac J Cancer Prev; 2013; 14(9):5199-205. PubMed ID: 24175801
[TBL] [Abstract][Full Text] [Related]
11. microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors.
Aguennouz M; Polito F; Visalli M; Vita G; Raffa G; Oteri R; Ghazi B; Scalia G; Angileri FF; Barresi V; Caffo M; Cardali S; Conti A; Macaione V; Bartolotta M; Giorgio RD; Germanò A
Cancer Treat Res Commun; 2020; 24():100203. PubMed ID: 32777750
[TBL] [Abstract][Full Text] [Related]
12. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
13. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
14. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer.
Song S; Honjo S; Jin J; Chang SS; Scott AW; Chen Q; Kalhor N; Correa AM; Hofstetter WL; Albarracin CT; Wu TT; Johnson RL; Hung MC; Ajani JA
Clin Cancer Res; 2015 Jun; 21(11):2580-90. PubMed ID: 25739674
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Kinase LATS2 Controls Helicobacter pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa.
Molina-Castro SE; Tiffon C; Giraud J; Boeuf H; Sifre E; Giese A; Belleannée G; Lehours P; Bessède E; Mégraud F; Dubus P; Staedel C; Varon C
Cell Mol Gastroenterol Hepatol; 2020; 9(2):257-276. PubMed ID: 31669263
[TBL] [Abstract][Full Text] [Related]
16. Methylation‑associated inactivation of LATS1 and its effect on demethylation or overexpression on YAP and cell biological function in human renal cell carcinoma.
Chen KH; He J; Wang DL; Cao JJ; Li MC; Zhao XM; Sheng X; Li WB; Liu WJ
Int J Oncol; 2014 Dec; 45(6):2511-21. PubMed ID: 25270913
[TBL] [Abstract][Full Text] [Related]
17. Hippo pathway and tumoral FOXP3 expression correlate with tumor growth in squamous cell carcinoma of the lung.
Won KY; Kim HK; Kim GY; Song MJ; Lim SJ
Pathol Res Pract; 2020 Jul; 216(7):153003. PubMed ID: 32534707
[TBL] [Abstract][Full Text] [Related]
18. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
Ito T; Nakamura A; Tanaka I; Tsuboi Y; Morikawa T; Nakajima J; Takai D; Fukayama M; Sekido Y; Niki T; Matsubara D; Murakami Y
Cancer Sci; 2019 Jul; 110(7):2284-2295. PubMed ID: 31069869
[TBL] [Abstract][Full Text] [Related]
19. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.
Jeong W; Kim SB; Sohn BH; Park YY; Park ES; Kim SC; Kim SS; Johnson RL; Birrer M; Bowtell DSL; Mills GB; Sood A; Lee JS
Anticancer Res; 2014 Feb; 34(2):811-817. PubMed ID: 24511017
[TBL] [Abstract][Full Text] [Related]
20. MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway.
Feng S; Sun H; Zhu W
Clin Transl Oncol; 2021 Mar; 23(3):450-458. PubMed ID: 32654106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
